DALLAS, Aug. 31, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Viral Genetics Inc. (Pink Sheets:VRAL). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Viral Genetics Inc. (Pink Sheets:VRAL) should be of particular interest to other pharmaceutical companies: Gilead Sciences Inc. (Nasdaq:GILD), GlaxoSmithKline plc (NYSE:GSK) and Bristol-Myers Squibb Co. (NYSE:BMY).
It is available at: http://www.beaconequity.com/i/VRAL
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Viral Genetics Inc. (VRAL) engages in the development of immune-based therapies for the treatment of HIV/AIDS. The Company's thymus nuclear protein compound has a potential to treat other diseases, such as autoimmune and immunological deficiencies.
In the report, the analyst notes:
"The market for the treatment of HIV/AIDS is rapidly changing, with $8 billion presently spent on drug therapies associated with the disease. Due to the mutation of the virus, the market leadership is changing. GlaxoSmithKline leads in the HIV/AIDS market, but is expected to succumb to research and development of other treatments by competitors as the virus mutates. According to analyst Mansi Shah of research firm Datamonitor, it's anticipated the market will increase by 50% by 2016, with two-thirds of HIV patents expiring during the next decade.
"On August 7, the Company announced it has formed a wholly owned subsidiary, MetaCytoLytics, to develop Metabolic Disruption Technology (MDT) to treat tumor cells by arresting glucose and other fatty acids from providing energy to the cancer cells. The technology has demonstrated its efficacy to directly cause cancer cells to die in animals. Synergizing techniques with other radiation therapies are also indicated in the study."
To read the entire report visit: http://www.beaconequity.com/i/VRAL
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report and small-cap research providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.